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Abstract
Background: During severe immunosuppression or treatment with specific biological drugs, human polyomavirus
JC (JCPyV) may establish a lytic infection in oligodendrocytes, leading to progressive multifocal
leukoencephalopathy (PML). Beyond AIDS, which represents the most common predisposing condition, several
biological drugs have been associated to the development of PML, such as natalizumab, fingolimod and dimethyl
fumarate, which have been showed to increase the risk of PML in the multiple sclerosis (MS) population. JCPyV
non-coding control region (NCCR) can be found in two different forms: a virulent neurotropic pathogenic form and
a latent non-pathogenic form. The neurotropic forms contain a rearranged NCCR and are typically found in the
cerebrospinal fluid, brain or blood of PML patients.
Case presentation: We sequenced and critically examined JCPyV NCCR from isolates detected in the cerebrospinal
fluid of four newly diagnosed progressive multifocal leukoencephalopathy patients: two HIV-positive and two HIV-
negative multiple sclerosis patients. More complex NCCR rearrangements were observed in the two HIV-positive
patients compared to the HIV-negative multiple sclerosis patients with PML.
Conclusions: The comparison of HIV-positive and HIV-negative MS patients with PML, allowed us to evidence the
presence of a common pattern of JCPyV NCCR rearrangement, characterized by the deletion of the D-block, which
could be one of the initial rearrangements of JCPyV NCCR needed for the development of PML.
Keywords: HIV, Multiple sclerosis, CSF, CNS, Disease-modifying therapies
Background
Progressive multifocal leukoencephalopathy (PML) is a
severe demyelinating disease of the central nervous sys-
tem (CNS) caused by the human polyomavirus JC
(JCPyV) [1]. Most of the people become seropositive to
JCPyV during childhood, and JCPyV can persist and rep-
licate asymptomatically in the urinary tract and in other
organs [2]. In immunocompetent subjects, the immune
system plays a fundamental role in controlling JCPyV
latent infection and the virus is rarely found outside of
the urinary tract [3]. During severe immunosuppression
or treatment with disease-modifying therapies (DMTs),
JCPyV may establish a lytic infection in oligodendro-
cytes, leading to PML [4, 5]. AIDS represents the most
common predisposing condition for PML development
[1]. However, the introduction of combination antiretro-
viral therapies (cART) have reduced the PML risk in
HIV-infected patients [1]. To date, several DMTs used
in multiple sclerosis (MS) have been associated with
PML. Natalizumab, fingolimod and dimethyl fumarate
have been associated with an increased risk of develop-
ing PML in the MS population [6]. The risk of
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developing natalizumab-associated PML depends on
three factors: the presence of anti-JC antibodies, a long
treatment duration (particularly longer than 24months)
and prior immunosuppressive drugs [7]. Although fingo-
limod and dimethyl fumarate can predispose to PML de-
velopment, the corresponding risk is significantly lower
than natalizumab [8]. Several cases of fingolimod-
associated PML have been reported, even excluding car-
ryover patients, coming from a previous natalizumab
therapy, and risk factors remain mostly unclear [9, 10].
Age and therapy duration seem to be relevant [8]. Gie-
selbach et al. have reviewed 19 PML cases associated
with fumaric acid esters including dimethyl fumarate in
MS [11].
JCPyV genome is characterized by the presence of
early and late genes, which encode for non-structural
and structural proteins, respectively, and are separated
by the non-coding control region (NCCR), which is a
key regulatory region of about 400 bp, harboring the ori-
gin of viral DNA replication ori, TATA-, TATA-like se-
quences, several transcription factor binding sites,
promoter/enhancer elements and the binding sites for
the viral large T-antigen [12]. Among the transcription
factor binding sites harbored in the NCCR, the nuclear
transcription factor-1 (NF-1) is a cell-specific regulator
of JCPyV promoter/enhancer activity [13]; the activating
protein 1 (AP-1) is a stimulatory factor involved in
JCPyV early gene expression in the absence of viral regu-
latory proteins [14]; the specificity protein-1 (SP-1) regu-
lates the JCPyV transcription [15]. One of the most
remarkable features of the JCPyV is the rearrangement
of the promoter/enhancer elements of the NCCR. In-
deed, duplications of the promoter/enhancer elements
and deletions of the suppressor elements [16]
characterize the virulent neurotropic pathogenic form
(prototype), which is typically found in the cerebrospinal
fluid (CSF), brain and blood of PML patients. Con-
versely, the non-rearranged form of NCCR is associated
to the non-pathogenic form (archetype), which is most
frequently detected in urine of healthy subjects as well
as PML patients [17].
Case presentation
The aim of this study was to evaluate and compare the
different rearrangements of the JCPyV NCCR sequences
detected in CSF samples of four newly diagnosed PML
patients with different risk factors: HIV infection and
DMTs treatment for MS. Specifically, we describe the
cases of two HIV-positive and two HIV-negative MS
patients who developed PML. PML diagnosis was
performed using magnetic resonance imaging (MRI) and
polymerase chain reaction (PCR) that revealed the pres-
ence of JCPyV-DNA in CSF samples. For each patient,
CSF samples were boiled for 10 min and then
centrifuged at 2000 g for 10 min. The resulting superna-
tants were used directly in molecular biology assays. To
detect and quantify the JCPyV genome copy numbers, a
7300 Real-Time quantitative PCR (qPCR) system
(Applied Biosystems, USA) was used employing specific
primers and probes [18]. Nested PCR with specific
primers flanking the NCCR and VP1 regions were per-
formed and PCR products corresponding to JCPyV
NCCR and VP1 regions were purified with the QIAquick
PCR purification kit, according to QIAGEN protocol
[19]. DNA sequencing was performed with a Sanger
protocol (Big Dye Terminator Sequencing, Life Tech-
nologies), using an ABI 3730 System (Life Technologies,
BioFab research s.r.l., Rome, Italy) and the sequences
were compared to the archetype CY strain using
Sequencing Analysis 5.2 Software (Life Technologies).
NCCR sequences have been deposited in Genbank (ac-
cession numbers MN241533, MN241534, MN241531,
MN241532).
Case 1
A 31-year-old Caucasian man with MS, after 24 natalizu-
mab infusion was switched to fingolimod due to the per-
sistent high anti-JCPyV antibody index (3.61). After 40
days of fingolimod treatment, the patient developed sei-
zures and visual field defects, leading to hospitalization.
The neurological examination revealed: lateral nystagmus
to the left, homonymous hemianopia, distal tremor and
spasm of the upper limbs. At hospital admission, the pa-
tient showed leukopenia (0.83 × 109/L). The brain MRI
showed multiple hyperintense areas in T2-weighted and
Fluid Attenuated Inversion Recovery (FLAIR) sequences,
in the frontal, occipital and parietal lobes of the right
hemisphere, with analogue smaller areas in the fronto-
parietal lobes of the left hemisphere. Brain lesions showed
poor contrast enhancement in T1-weighted sequences.
Suspecting PML, a lumbar puncture (LP) was per-
formed. The CSF composition is reported in Table 1.
Furthermore, JCPyV-DNA was detected in CSF (1.62 ×
106 IU/mL) by qPCR. Considering clinical presentation,
MRI imaging and JCPyV-DNA detection in CSF, the
PML diagnosis was confirmed. The patient was treated
with mannitol and high dose corticosteroids for 5 days.
As reported in Fig. 1, the JCPyV NCCR analysis
showed the following block organization: A–B*–C–E–F,
with deletion of nucleotides from 117 to 180, corre-
sponding to D-block. Moreover, in B-block, a T to G nu-
cleotide transversion in position 37, corresponding to
the Spi-B binding site, was found (which is indicated by
the asterisks next to the relative block). VP1 coding re-
gion was also sequenced and showed a wild type
organization without any mutations.
One month after hospitalization, neurological examin-
ation improved significantly, and JCV-DNA became
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undetectable in CSF sample. Three months after
hospitalization, brain MRI showed a reduction in the
number of the lesions.
Case 2
A 41-year-old Caucasian woman with MS started di-
methyl fumarate. After 21 months, the patient showed
partial disorientation in space and time, nystagmus, left
motor syndrome, tremor, dysmetria, paresthesia, speech
disorder and cognitive impairment with short term
memory loss, which led to dimethyl fumarate discon-
tinuation. At hospital admission, the patient showed
leukopenia (0.88 × 109/L). The brain MRI showed hyper-
intensity in T2 weighted sequences, with homogeneous
enhancement in both cortical and subcortical areas of
the frontal, parietal and temporal lobes of the left hemi-
sphere. Suspecting PML, LP was performed. The CSF
composition is reported in Table 1. JCPyV-DNA was de-
tected in CSF (4.9 × 105 IU/mL) by qPCR. The patient
was treated with mannitol and high dose corticosteroids
for 5 days.
JCPyV-NCCR was sequenced showing the following
organization: A–B–C–(D)–E–F (block in brackets means
presence of rearrangements). Specifically, D-block was
characterized by a 64-nuclueotide deletion (from 127 to
180), with only 10 remaining nucleotides (from 117 to
126) (Fig. 1). VP1 sequence analysis did not show any
mutations.
Three months after hospitalization, JCV-DNA was un-
detectable in CSF and a brain MRI showed the reduction
in the number of the lesions.
Case 3
A 61-year-old Caucasian man with a medical history in-
cluding eradicated Hepatitis C virus (HCV) infection, dia-
betes mellitus-associated neuropathy, leukopenia, previous
herpes zoster infection, was admitted to the hospital be-
cause of cognitive impairment, motor disfunctions and
speech defects. HIV test was performed and was positive.
HIV plasma viral load was 2.4 × 106 IU/mL, CD4 cell
count was 71 cells/μL, CD8 cell count was 728 cells/μL
(CD4/CD8 ratio: 0.10). The neurological examination
showed left homonymous hemianopia and astereognosia.
A computed tomography (CT) scan of the brain showed
hypodensities in the right frontal lobe and in the semioval
center. Brain MRI confirmed the presence of T2 weighted
and FLAIR sequences hyperintensities in the cortical and
subcortical regions of the occipital and parietal right lobes
and in the semioval center, without remarkable post-
contrast enhancement in T1 weighted sequences. The
CSF composition is reported in Table 1. JCPyV-DNA was
detected in the CSF (8.97 × 105 IU/mL) by qPCR. Typical
Fig. 1 The JCPyV NCCR sequences from CSF of four PML patients. The JCPyVNCCR sits between the viral early gene large T and the late gene
agnoprotein and is a 267 base pairs sequence, in the archetype CY strain. The 267 bases are conventionally organized into 6 unequal fragments,
namely from A to F: A from 1 to 36, B from 37 to 59, C from 60 to 114, D from 115 to 180, E from 181 to 198, F from 199 to 267 bases [12, 20].
Archetype CY and Mad-1 NCCRs are shown for comparison. Delated blocks are represented in grey with dotted lines. Asterisk (*) represents single
nucleotide polymorphism. Transcription factor binding sites are represented by triangles. TATA: tata box; LCP: lytic control element-binding
protein; SP-1: specificity protein-1; NF-1a: nuclear transcription factor 1a; SF2/ASF: splicing factor 2/alternative spicing factor; NF-1b: nuclear
transcription factor-1b; AP-1: activating protein-1
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clinical and radiological findings and JCPyV-DNA detec-
tion in the CSF confirmed the PML diagnosis. The patient
received mannitol and steroid therapy. The patient was
started with antiretroviral therapy with tenofovir diso-
proxil fumarate/emtricitabine and dolutegravir.
JCPyV NCCR sequencing showed the following
organization: A-B-(C)-(E)-(F)-(B)-(C)-(E)-F*. Specifically,
C-block was partially deleted (first 38 nucleotides were
maintained, out of 55), D-block was fully deleted (from
117 to 180), E-block (the last 9 nucleotides were main-
tained, out of 18) and F-block (the first 5 nucleotides
were maintained, out of 69) were partially deleted.
Furthermore, duplications from nucleotide 54 to 59 of
B-block, from 60 to 87 of C-block, from 189 to 198 of E-
block and complete of F-block, with a 217 G to A point
mutation, were found (Fig. 1). The isolated strain
showed one-point mutation (S269F) of VP1 gene, within
the VP1 receptor-binding region. One month after
hospitalization, a new brain MRI showed disease pro-
gression with left hemisphere involvement. The patient
was discharged and transferred to a reeducation center.
Case 4
A 68-year-old Indian man with a six-month history of
weight loss, sweating, dry cough, low-grade fever and
presence of violet papules on the right leg was admitted
to the hospital. Chest x-ray showed thickening in the
peribronchial areas associated to diffuse alveolar filling.
The patient started antibiotic therapy with intravenous
ceftriaxone and oral azithromycin. HIV test was per-
formed and was positive. HIV viral load was 3.8 × 105
IU/mL, CD4 cell count was 35 cells/μL, CD8 cell count
was 306 cells/μL (CD4/CD8 ratio: 0.11). The patient
started antiretroviral therapy with tenofovir disoproxil
fumarate/emtricitabine and raltegravir. CT scan of the
brain showed two hypodense subcortical areas in the left
temporal lobe without significant mass effect. Brain MRI
showed an area of hypointensity in T1-weighted and
hyperintensity in T2-weighted sequences of the left oc-
cipital and temporal lobes and peritrigonal regions, with-
out remarkable contrast enhancement. The CSF
composition is reported in Table 1. JCPyV-DNA was de-
tected in the CSF (2.34 × 106 IU/mL) by qPCR. PML
diagnosis was confirmed. Patient was treated with daru-
navir/ritonavir in addition to the previously indicated
antiretroviral treatment.
The JCPyV NCCR sequencing revealed the following
block organization: A–C*–E*–F*. Nucleotides 37–59 and
117–180, corresponding to B- and D-block, respectively,
were completely deleted. The complete deletions of the
B- and D-block implied the loss of both Sp-1 binding
sites. Single-nucleotide differences were found in C-
block (100 A to C), E-block (183 T to A) and F-block
with a characteristic 217 G to A point mutation (Fig. 1).
VP1 region sequencing revealed a single mutation caus-
ing the amino acid change S267 L involving the
receptor-binding region of VP1. One month after
hospitalization, a new brain MRI showed disease pro-
gression with right hemisphere involvement. The patient
was discharged and transferred to a reeducation center.
Discussion and conclusions
The emergence of PML in MS patients under immunosup-
pressive therapies and DMTs, such as natalizumab, moti-
vated a search for biological factors contributing to the risk
of this serious brain infection [21], such as T-lymphocytes
changes [22, 23] and matrix metalloproteinase-9 enzymatic
activity [24]. The CNS immune surveillance impairment,
the reactivation of latent JCPyV and the blood-brain barrier
damage can explain the increased risk of PML development
in natalizumab-treated MS patients. Concerning PML in di-
methyl fumarate-treated MS patients, only five confirmed
cases have been reported, so far [11]. Although the pres-
ence of JCPyV in the CNS has been established in all con-
firmed cases of PML under DMTs, the JCPyV NCCR was
not constantly sequenced.
In this study, we characterized JCPyV NCCR sequences
detected in the CSF samples of four newly diagnosed PML
patients. The JCPyV NCCR analyses revealed a variety of
rearranged patterns, which differed from the archetype
structure described for the CY strain by Yogo and col-
leagues [17]. In all cases, the JCPyV NCCR isolates were
characterized by partial or complete deletion and duplica-
tion of some blocks. Different sequence variations had a
similar potential of upregulating viral early gene expres-
sion. Similarly to naturally occurring rearranged NCCR of
BK virus in kidney transplant patients [25], JCPyV NCCR
duplications were found more often in the left blocks A to
C, close to the origin of genome replication, while dele-
tions were more frequent in the right end, close to the late
genes [26]. A simple hypothesis is that deletions in the
proximity of the late genes represent a loss of function, re-
moving a suppressing control transcriptional sequence,
whereas duplications in the left end of the NCCR repre-
sent a gain of function, increasing activating control se-
quences that enhance viral replication and gene
transcription [27].
As have been previously described by other authors,
the TATA box and the first half of the C-block appear
to be indispensable for viral replication. This portion of
the C-block contains NF-1 binding site that is a cell-
specific regulator in JCPyV early transcription and repli-
cation [13]. In the C-block, immediately adjacent to the
NF-1 site, there is the AP-1 binding site, a stimulatory
factor involved in JCPyV early gene expression in the ab-
sence of viral regulatory proteins [14]. A consensus rec-
ognition sequence for the transcription factor SP-1
exists in the B-block. SP-1 is necessary for simian virus
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40 (SV40) transcription [28], and can bind to the SP-1
homology region in BKV [29] as well as the JCV pro-
moter [30].
We observed a more complex NCCR rearrangement in
the two HIV-positive patients compared to the two HIV-
negative MS patients. Several factor can contribute to the
higher grade of JCPyV NCCR rearrangement in HIV-
positive patients: the severity of immune impairment,
colocalization of HIV and JCPyV in the brain and HIV
interaction with JCPyV replication, mediated by viral fac-
tors, such as HIV Tat protein [31, 32]. Specifically, HIV
Tat is able to increase the viral early gene expression of
the JCPyV archetype, to a level that is comparable to the
intrinsic activity of the JCPyV strains with a rearranged
NCCR [33]. Therefore, it could be speculated an inter-
action between the two viruses with possible enhancement
of JCPyV replication due to the presence of HIV TAT
protein, and a more rapid viral evolution with a more
complex rearrangement of the NCCR.
In all patients, the JCPyV NCCR was characterized by
the complete (case 1, 3 and 4) or partial (case 2) D-block
deletion. A higher JCPyV viral load and a lower CD4/CD8
ratio were recorded in those cases characterized by a
NCCR with a complete D-block deletion (case 1, 3 and 4).
As shown by other authors, this evidence could suggest
the role of CD4+ T-cells in controlling viral replication
and how the CD8+ T cells cytotoxic response, although
important, is not sufficient to prevent PML [34].
Concerning the two HIV-positive patients, we ob-
served JCPyV NCCR rearrangements with both deletions
and duplications in case 3 and with deletion only in case
4. As showed by other authors, during NCCR rearrange-
ment, deletions may occur prior to duplications [35].
The analysis of transcription factor binding site modifi-
cations within the JCPyV NCCR, revealed that the NF-1
binding site was duplicated in the viral isolate from one
HIV-positive patient (case 3), with duplications of other
sites such as the AP-1 and SP-1. Interestingly, partial C-
block deletion involved the SF2/ASF binding site, a cel-
lular alternative splicing factor, which targets this unique
sequence within JCPyV NCCR and strongly inhibits viral
transcription and viral propagation in glial cells [36].
The loss of the SF2/ASF binding site could explain the
lower viral load found in the case 3, probably due to the
impairment of late gene transcription, in which SF2/ASF
plays a crucial role for its initiation [37].
Finally, we sequenced the VP1 region of the four iso-
lates. In the two HIV-positive patients point mutations
were found in the VP1 coding region (S269F in case 3
and S267 L in case 4). These mutations occurred in VP1
sites for sialic acid binding, changing the virus’s binding
properties to its receptor or driving to alternative recep-
tor usage. It has been speculated that mutations within
this site may alter the preference of JCPyV capsids from
sialylated glycans outside the CNS to non-sialylated gly-
cans inside the CNS, which might explain infection and
replication in glial cells [20, 38–41].
JCPyV NCCR rearrangements and VP1 mutations may
be independent events that impact distinct elements of
JCPyV cellular tropism. However, since VP1 mutations
have not been observed in JCPyV with archetype NCCR,
VP1 mutations may only arise in JCPyV with the NCCR
pathogenic forms [35].
Given the low incidence of PML, the number of pa-
tients observed in this preliminary study is very small,
thus limiting the general applicability of our findings.
Despite this limitation, one of the most relevant evi-
dence of this study is that the complete or partial D-
block deletion seems to be an early and crucial re-
arrangement of NCCR for the development of PML.
Interestingly, D-block deletion was the only finding of
NCCR sequence rearrangement in the two MS patients
with confirmed PML. Differently from HIV late pre-
senters with advanced disease, in MS patients the onset
of the immune dysregulation leading to PML, can be
easily identified and usually corresponds to the biologic
treatment initiation. JCPyV PCR on CSF remains the
gold standard for PML diagnosis. Considering the
awareness of clinicians about the risk of PML in MS pa-
tients under immune modulating therapies, CSF is
promptly collected and JCPyV PCR is rapidly performed,
when there is such a suspicion. This usually allows the
sudden identification of PML in the early stages of the
disease. Consequently, the detection of JCPyV-DNA in
the CSF early in the history of PML can reveal the pres-
ence of a NCCR at the beginning of the sequence of re-
arrangement events.
According to these considerations, we speculate that D-
block deletion observed as the only rearrangement in the
two MS patients, but also present in the two HIV late pre-
senters, could represent one of the early but crucial steps
in the complex series of NCCR rearrangements leading to
PML. Considering the limited number of cases reported
here, it is difficult to establish a correlation between the
outcome and the type of rearrangements observed in the
JCPyV NCCR. Moreover, MS patients showed a better
prognosis, probably because of the discontinuation of the
DMT and consequent immune reconstitution. Indeed,
after DMT removal, MS patients with PML can experi-
ence an immune reconstitution syndrome (IRIS), which is
similar to PML-IRIS occurring in some HIV patients after
cART initiation [1].
One limitation of our study is represented by the use
of the classical Sanger method for sequencing JCPyV
NCCR. Several innovative techniques for identifying and
sequencing viral strains are now available. As showed by
Seppälä et al., next generation sequencing (NGS) has the
ability to characterize JCPyV NCCR with more accuracy,
Ciardi et al. Virology Journal           (2020) 17:23 Page 6 of 8
identifying minority variants and multiple strains with
different rearrangements within the same individual
[42]. Although in this study we used the Sanger method,
NGS represent a promising approach for identifying
JCPyV minority variants and understanding viral
evolution.
These preliminary data could stimulate additional re-
searches on wider cohorts involving HIV-positive and
HIV-negative patients to determine whether the changes
observed in our patients are consistently present. More-
over, tissue distribution of JCPyV in healthy subjects and
patients with HIV or MS needs to be assessed, as well as
longitudinal studies in patients under DMTs with PML
risk, in order to clarify the pathogenesis of JCPyV reacti-
vation and PML onset. These translational approaches
should be associated with improved methods for detec-
tion of low JCPyV viral load in the CSF and blood sam-
ples, which may help in better defining the risk of
developing PML in susceptible categories of patients.
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